Skip to content
OpenCapital
Get started

Bausch Health Companies BHC Product rebates

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$1.86B-15.9%

Profitability

See full
Gross margin71.4%—
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%—
Debt / equity45.2×—
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept bhc:AccruedProductRebateCurrent.

The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Bausch Health Companies's product rebates?
Bausch Health Companies (BHC) reported product rebates of $1.12B in Q1 2026.
How has Bausch Health Companies's product rebates changed year-over-year?
Bausch Health Companies's product rebates decreased by 15.4% year-over-year, from $1.32B to $1.12B.
What is the long-term trend for Bausch Health Companies's product rebates?
Over 3 years (2022 to 2025), Bausch Health Companies's product rebates has grown at a 10.4% compound annual growth rate (CAGR), from $983M to $1.32B.